ENTRY       D04820                      Drug
NAME        Lurasidone hydrochloride (JAN/USAN);
            SM 13496;
            Latuda (TN)
PRODUCT     LATUDA (Sumitomo Pharma America)
  GENERIC   LURASIDONE HYDROCHLORIDE (A-S Medication Solutions)
            LURASIDONE HYDROCHLORIDE (Accord Healthcare)
            LURASIDONE HYDROCHLORIDE (Alembic Pharmaceuticals Limited)
            LURASIDONE HYDROCHLORIDE (Alembic Pharmaceuticals)
            LURASIDONE HYDROCHLORIDE (American Health Packaging)
            LURASIDONE HYDROCHLORIDE (Amneal Pharmaceuticals LLC)
            LURASIDONE HYDROCHLORIDE (Ascend Laboratories)
            LURASIDONE HYDROCHLORIDE (Aurobindo Pharma Limited)
            LURASIDONE HYDROCHLORIDE (Cipla USA)
            LURASIDONE HYDROCHLORIDE (Dr. Reddys Laboratories)
            LURASIDONE HYDROCHLORIDE (Dr. Reddys Laboratories)
            LURASIDONE HYDROCHLORIDE (Exelan Pharmaceuticals)
            LURASIDONE HYDROCHLORIDE (Lupin Pharmaceuticals)
            LURASIDONE HYDROCHLORIDE (Macleods Pharmaceuticals Limited)
            LURASIDONE HYDROCHLORIDE (Major Pharmaceuticals)
            LURASIDONE HYDROCHLORIDE (Novadoz Pharmaceuticals LLC)
            LURASIDONE HYDROCHLORIDE (REMEDYREPACK)
            LURASIDONE HYDROCHLORIDE (REMEDYREPACK)
            LURASIDONE HYDROCHLORIDE (Slate Run Pharmaceuticals)
            LURASIDONE HYDROCHLORIDE (Sun Pharmaceutical Industries)
            LURASIDONE HYDROCHLORIDE (Torrent Pharmaceuticals Limited)
            LURASIDONE HYDROCHLORIDE (Torrent Pharmaceuticals Limited)
            LURASIDONE HYDROCHLORIDE (Zydus Lifesciences Limited)
            LURASIDONE HYDROCHLORIDE (Zydus Pharmaceuticals USA)
FORMULA     C28H36N4O2S. HCl
EXACT_MASS  528.2326
MOL_WEIGHT  529.137
CLASS       Neuropsychiatric agent
             DG01483  5-HT1A-receptor agonist
             DG01472  Dopamine agonist
              DG01468  Dopamine D2-receptor agonist
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 1179
            ATC code: N05AE05
            Product: D04820<JP/US>
EFFICACY    Antipsychotic, Serotonin receptor antagonist, Dopamine D2 receptor antagonist
  DISEASE   Schizophrenia [DS:H01649]
            Bipolar I disorder [DS:H01653]
COMMENT     atypical antipsychotic
            Treatment of schizophrenia
TARGET      DRD2 [HSA:1813] [KO:K04145]
            HTR2A [HSA:3356] [KO:K04157]
  PATHWAY   hsa04080(1813+3356)  Neuroactive ligand-receptor interaction
            hsa04726(3356)  Serotonergic synapse
            hsa04728(1813)  Dopaminergic synapse
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N05 PSYCHOLEPTICS
               N05A ANTIPSYCHOTICS
                N05AE Indole derivatives
                 N05AE05 Lurasidone
                  D04820  Lurasidone hydrochloride (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antipsychotics
              2nd Generation/Atypical
               Lurasidone
                D04820  Lurasidone hydrochloride (JAN/USAN)
             Bipolar Agents
              Bipolar Agents, Other
               Lurasidone
                D04820  Lurasidone hydrochloride (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               117  Psychotropics
                1179  Others
                 D04820  Lurasidone hydrochloride (JAN/USAN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01483  5-HT1A-receptor agonist
               D04820  Lurasidone hydrochloride
              DG01472  Dopamine agonist
               DG01468  Dopamine D2-receptor agonist
                D04820  Lurasidone hydrochloride
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D04820  Lurasidone hydrochloride
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Dopamine
                DRD2
                 D04820  Lurasidone hydrochloride (JAN/USAN) &lt;JP/US&gt;
               Serotonin
                HTR2A
                 D04820  Lurasidone hydrochloride (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D04820
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D04820
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D04820
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D04820
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D04820
DBLINKS     CAS: 367514-88-3
            PubChem: 47206606
            ChEBI: 70732
            LigandBox: D04820
ATOM        36
            1   C1y C    32.7876  -16.5933
            2   C1x C    33.4857  -15.3366
            3   C1x C    32.7178  -14.1498
            4   C1x C    31.3215  -14.1496
            5   C1x C    30.6931  -15.4064
            6   C1y C    31.3913  -16.5933
            7   C1x C    39.5595  -17.0122
            8   C1x C    39.5595  -18.4085
            9   C1y C    38.3029  -19.1066
            10  C1y C    37.0462  -18.4085
            11  C1y C    37.0462  -17.0122
            12  C1y C    38.2331  -16.3140
            13  C5x C    35.7896  -18.8273
            14  N1y N    34.8820  -17.7801
            15  C5x C    35.7198  -16.5933
            16  O5x O    35.3707  -15.2668
            17  O5x O    35.3707  -20.1538
            18  C1x C    37.8840  -17.6405
            19  C1b C    33.5555  -17.7801
            20  C1b C    30.7630  -17.7801
            21  N1y N    29.3667  -17.7799
            22  C1x C    28.6685  -16.5931
            23  C1x C    27.2722  -16.5931
            24  N1y N    26.5741  -17.8498
            25  C1x C    27.3421  -19.0366
            26  C1x C    28.7383  -19.0368
            27  C8y C    25.1778  -17.8498
            28  C8y C    24.3401  -16.7327
            29  C8y C    23.0136  -17.2214
            30  S2x S    23.0136  -18.6177
            31  N5x N    24.4099  -19.0366
            32  C8x C    24.6193  -15.3364
            33  C8x C    23.5721  -14.4289
            34  C8x C    22.2456  -14.9176
            35  C8x C    21.9664  -16.3138
            36  X   Cl   42.2125  -17.9198
BOND        41
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     7   8 1
            8     8   9 1
            9     9  10 1
            10   10  11 1
            11   11  12 1
            12    7  12 1
            13   13  14 1
            14   14  15 1
            15   11  15 1
            16   15  16 2
            17   13  17 2
            18   12  18 1 #Up
            19    9  18 1 #Up
            20   10  13 1
            21   14  19 1
            22    1  19 1 #Up
            23    6  20 1 #Down
            24   20  21 1
            25   21  22 1
            26   22  23 1
            27   23  24 1
            28   24  25 1
            29   25  26 1
            30   21  26 1
            31   24  27 1
            32   27  28 1
            33   28  29 1
            34   29  30 1
            35   30  31 1
            36   27  31 2
            37   28  32 2
            38   32  33 1
            39   33  34 2
            40   34  35 1
            41   29  35 2
///
